Entera Bio (NASDAQ:ENTX) Coverage Initiated at Leerink Partners

Analysts at Leerink Partners initiated coverage on shares of Entera Bio (NASDAQ:ENTX) in a research report issued to clients and investors on Friday, Briefing.com reports. The brokerage set an “outperform” rating and a $9.00 price target on the stock. Leerink Partners’ price objective points to a potential upside of 197.03% from the stock’s current price.

Several other analysts have also recently weighed in on the stock. HC Wainwright reissued a “buy” rating on shares of Entera Bio in a research note on Wednesday, June 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Entera Bio in a research report on Friday, July 17th. Finally, Wall Street Zen upgraded Entera Bio to a “sell” rating in a report on Saturday, August 8th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $9.00.

Entera Bio Stock Performance

Shares of ENTX opened at $3.03 on Friday. Entera Bio has a 52 week low of $0.91 and a 52 week high of $4.20. The stock has a market capitalization of $526.70 million, a price-to-earnings ratio of -8.66 and a beta of 1.38. The stock has a fifty day moving average of $2.77 and a 200-day moving average of $1.81.

Entera Bio (NASDAQ:ENTX) last issued its quarterly earnings data on Friday, August 7th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.06).

Institutional Trading of Entera Bio

A hedge fund recently raised its position in Entera Bio stock. Seven Fleet Capital Management LP raised its holdings in shares of Entera Bio Ltd. (NASDAQ:ENTX) by 51.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 205,542 shares of the company’s stock after purchasing an additional 70,224 shares during the quarter. Seven Fleet Capital Management LP owned approximately 0.42% of Entera Bio worth $228,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 14.11% of the company’s stock.

About Entera Bio

Entera Bio Ltd. is a biotechnology company developing orally administered therapies based on large-molecule drugs, including proteins and peptides that are traditionally delivered by injection. The company’s proprietary delivery technology is designed to help these molecules pass through the gastrointestinal tract and reach the bloodstream, with the goal of improving convenience and patient adherence.

Entera Bio’s lead programs have focused on bone and mineral disorders. Its pipeline has included EB613, an oral formulation of parathyroid hormone (PTH 1-34, or teriparatide) being developed for the treatment of osteoporosis, and EB612, an oral PTH product candidate intended for hypoparathyroidism.